Synergy Pharmaceuticals, Inc Common Stock
SGYP
SGYP was delisted on the 7th of March, 2019.
133 hedge funds and large institutions have $164M invested in Synergy Pharmaceuticals, Inc Common Stock in 2018 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 30 increasing their positions, 36 reducing their positions, and 20 closing their positions.
4% less capital invested
Capital invested by funds: $170M → $164M (-$6.35M)
2% less funds holding
Funds holding: 136 → 133 (-3)
15% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 20
17% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 36
43% less call options, than puts
Call options by funds: $2.63M | Put options by funds: $4.61M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.19M |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
+$1.73M |
| 3 |
NC
Nexthera Capital
New York
|
+$1.34M |
| 4 |
BlackRock
New York
|
+$1.02M |
| 5 |
CEP
Chicago Equity Partners
Chicago,
Illinois
|
+$512K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$5.93M |
| 2 |
State Street
Boston,
Massachusetts
|
-$2.23M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$1.2M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$455K |
| 5 |
DMK
David M. Knott
|
-$392K |
SGYP Hedge Fund Activity: Q3 2018 in Review
133 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals, Inc Common Stock (SGYP) for Q3 2018, worth a combined $164M — down 3.7% from $170M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of SGYP and 17 opened new positions — a net loss of 3 holders — while 36 trimmed existing stakes and 30 added.
The largest buyer was Vanguard Group, adding an estimated $2.19M. The largest seller was Nantahala Capital Management, cutting an estimated $5.93M.
- 133 institutional investors held Synergy Pharmaceuticals, Inc Common Stock (SGYP) as of Q3 2018, down from 136 in Q2 2018.
- Funds reported $164M of Synergy Pharmaceuticals, Inc Common Stock stock for Q3 2018, down 3.7% quarter-over-quarter.
- 17 funds opened new Synergy Pharmaceuticals, Inc Common Stock positions in Q3 2018 and 20 closed out, a net change of -3 holders.
- The largest Synergy Pharmaceuticals, Inc Common Stock buyer in Q3 2018 was Vanguard Group, an estimated $2.19M added.
- The largest Synergy Pharmaceuticals, Inc Common Stock seller in Q3 2018 was Nantahala Capital Management, an estimated $5.93M sold.
Based on aggregated 13F filings for Q3 2018.